Crizotinib

Products

Inquiry

Cat. No.: IBDI-433389

Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition.

Size (Solution): 10 mM * 1 mL in DMSO

Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution

Size (Solid):

Product Details

Target	Anaplastic lymphoma kinase (ALK) \| c-Met/HGFR \| ROS Kinase \| Autophagy
Molecular Weight	450.34
Appearance	Solid
Synonyms	PF-02341066
SMILES	ClC1=C(F)C=CC(Cl)=C1[[email protected]](OC2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N)C
Purity	99.83%

Storage & Handling

Shipping	Room temperature in continental US. May vary elsewhere.
Storage	Powder: -20°C/3 years; 4°C/2 years In solvent: -80°C/6 months; -20°C/1 month
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.

! For research use only, not intended for any clinical use.